Record Information |
---|
Version | 5.0 |
---|
Status | Detected and Quantified |
---|
Creation Date | 2006-05-22 14:17:34 UTC |
---|
Update Date | 2021-10-13 04:37:16 UTC |
---|
HMDB ID | HMDB0002061 |
---|
Secondary Accession Numbers | - HMDB0006554
- HMDB0010366
- HMDB02061
- HMDB06554
- HMDB10366
|
---|
Metabolite Identification |
---|
Common Name | Hyaluronic acid |
---|
Description | Hyaluronic acid (HA) is the most abundant glycosaminoglycan (GAG) in mammalian tissue. It is present in high concentrations in connective tissue, such as skin, vitreous humour, cartilage, and umbilical cord, but the largest single reservoir is the synovial fluid (SF) of the diarthrodial joints, where concentrations of 0.5-4 mg/mL are achieved. Hyaluronic acid is the major hydrodynamic nonprotein component of joint SF. Its unique viscoelastic properties confer remarkable shock absorbing and lubricating abilities to SF, while its enormous macromolecular size and hydrophilicity serve to retain fluid in the joint cavity during articulation. HA restricts the entry of large plasma proteins and cells into SF but facilitates solute exchange between the synovial capillaries and cartilage and other joint tissues. In addition, HA can form a pericellular coat around cells, interact with proinflammatory mediators, and bind to cell receptors, such as cluster determinant (CD)44 and receptor for hyaluronate-mediated motility (RHAMM), where it modulates cell proliferation, migration, and gene expression. All these physicochemical and biologic properties of HA have been shown to be molecular weight (MW) dependent. The diverse physicochemical properties of HA arise from its unique macromolecular structure. The HA is an exceptionally long (3-30 μm) and unbranched nonsulfated GAG composed of repeating disaccharide units of N-acetylglucosamine and glucuronic acid glycosidically linked through their respective 1-4 ring positions. Hydroxyl group oxygens at the glucuronyl-1 and glucosamine 3-positions are used for further polymerization of the HA disaccharide units to form chains that, when released from the cell plasma membrane, are of variable length and thus polydispersity. Despite the simplicity of the HA primary structure, this linear polyelectrolyte adopts complex conformations in solution, which engender it with diverse biologic properties. Within the joint cavity, HA molecules are predominately synthesized by the type B synovial cells (PMID: 12219318 ). |
---|
Structure | [H]O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2C(O)=O)[C@@H]1NC(C)=O InChI=1S/C14H23NO12/c1-3(17)15-5-7(19)6(18)4(2-16)25-14(5)27-10-8(20)9(21)13(24)26-11(10)12(22)23/h4-11,13-14,16,18-21,24H,2H2,1H3,(H,15,17)(H,22,23)/t4-,5-,6-,7-,8-,9-,10+,11+,13-,14+/m1/s1 |
---|
Synonyms | Value | Source |
---|
(2S,3S,4R,5R,6R)-3-[(2S,3R,4R,5S,6R)-3-Acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid | ChEBI | 2-Acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1->4)-beta-D-gluco-hexopyranuronic acid | ChEBI | WURCS=2.0/2,2,1/[a2122a-1b_1-5][a2122h-1b_1-5_2*ncc/3=o]/1-2/a4-b1 | ChEBI | (2S,3S,4R,5R,6R)-3-[(2S,3R,4R,5S,6R)-3-Acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylate | Generator | 2-Acetamido-2-deoxy-b-D-gluco-hexopyranosyl-(1->4)-b-D-gluco-hexopyranuronate | Generator | 2-Acetamido-2-deoxy-b-D-gluco-hexopyranosyl-(1->4)-b-D-gluco-hexopyranuronic acid | Generator | 2-Acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1->4)-beta-D-gluco-hexopyranuronate | Generator | 2-Acetamido-2-deoxy-β-D-gluco-hexopyranosyl-(1->4)-β-D-gluco-hexopyranuronate | Generator | 2-Acetamido-2-deoxy-β-D-gluco-hexopyranosyl-(1->4)-β-D-gluco-hexopyranuronic acid | Generator | Hyaluronate | Generator | Hyaluronan | HMDB | (2S,3S,4R,5R,6R)-3-{[(2S,3R,4R,5S,6R)-4,5-dihydroxy-3-[(1-hydroxyethylidene)amino]-6-(hydroxymethyl)oxan-2-yl]oxy}-4,5,6-trihydroxyoxane-2-carboxylate | HMDB |
|
---|
Chemical Formula | (C14H21NO11)nH2O |
---|
Average Molecular Weight | Not Available |
---|
Monoisotopic Molecular Weight | Not Available |
---|
IUPAC Name | Not Available |
---|
Traditional Name | Not Available |
---|
CAS Registry Number | 9004-61-9 |
---|
SMILES | [H]O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2C(O)=O)[C@@H]1NC(C)=O |
---|
InChI Identifier | InChI=1S/C14H23NO12/c1-3(17)15-5-7(19)6(18)4(2-16)25-14(5)27-10-8(20)9(21)13(24)26-11(10)12(22)23/h4-11,13-14,16,18-21,24H,2H2,1H3,(H,15,17)(H,22,23)/t4-,5-,6-,7-,8-,9-,10+,11+,13-,14+/m1/s1 |
---|
InChI Key | LJKKEBYAXYCTNF-GIXQJHCPSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as n-acyl-alpha-hexosamines. These are carbohydrate derivatives containing a hexose moiety in which the oxygen atom is replaced by an n-acyl group. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organic oxygen compounds |
---|
Class | Organooxygen compounds |
---|
Sub Class | Carbohydrates and carbohydrate conjugates |
---|
Direct Parent | N-acyl-alpha-hexosamines |
---|
Alternative Parents | |
---|
Substituents | - Fatty acyl glycoside
- Fatty acyl glycoside of mono- or disaccharide
- N-acyl-alpha-hexosamine
- Glucuronic acid or derivatives
- Disaccharide
- Glycosyl compound
- O-glycosyl compound
- Pyran
- Fatty acyl
- Oxane
- Acetamide
- Secondary carboxylic acid amide
- Secondary alcohol
- Carboxamide group
- Hemiacetal
- Oxacycle
- Organoheterocyclic compound
- Polyol
- Carboxylic acid derivative
- Carboxylic acid
- Acetal
- Monocarboxylic acid or derivatives
- Organic nitrogen compound
- Carbonyl group
- Organopnictogen compound
- Organic oxide
- Alcohol
- Organonitrogen compound
- Primary alcohol
- Hydrocarbon derivative
- Aliphatic heteromonocyclic compound
|
---|
Molecular Framework | Aliphatic heteromonocyclic compounds |
---|
External Descriptors | Not Available |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | |
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredictor | Adduct Type | CCS Value (Å2) | Reference |
---|
DeepCCS | [M+H]+ | 190.853 | 30932474 | DeepCCS | [M-H]- | 188.989 | 30932474 | DeepCCS | [M-2H]- | 222.369 | 30932474 | DeepCCS | [M+Na]+ | 196.486 | 30932474 |
Predicted Kovats Retention IndicesNot Available |
---|
Spectra |
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Hyaluronic acid GC-MS (TMS_2_11) - 70eV, Positive | Not Available | 2022-08-08 | Wishart Lab | View Spectrum | MS | Mass Spectrum (Electron Ionization) | Not Available | 2022-08-06 | Not Available | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Hyaluronic acid 10V, Positive-QTOF | splash10-001j-0109000000-aa608ebc95d3c41aa119 | 2019-02-22 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Hyaluronic acid 20V, Positive-QTOF | splash10-004j-1904000000-f499cfd0131b9f9a2980 | 2019-02-22 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Hyaluronic acid 40V, Positive-QTOF | splash10-01rm-5913000000-b22d6d78477b0b69bd4e | 2019-02-22 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Hyaluronic acid 10V, Negative-QTOF | splash10-0kdv-3359000000-4a1c55483243aa363f3b | 2019-02-23 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Hyaluronic acid 20V, Negative-QTOF | splash10-0059-4898000000-c9c9f151634e6af628e3 | 2019-02-23 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Hyaluronic acid 40V, Negative-QTOF | splash10-05gi-8890000000-0e073a162fbb99c31d01 | 2019-02-23 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Hyaluronic acid 10V, Positive-QTOF | splash10-0002-0009000000-723f981753eca3762215 | 2021-09-23 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Hyaluronic acid 20V, Positive-QTOF | splash10-0012-0329000000-91a530fe4b8b4d73a0dc | 2021-09-23 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Hyaluronic acid 40V, Positive-QTOF | splash10-0a4u-9410000000-0d005698920dfdb4eeff | 2021-09-23 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Hyaluronic acid 10V, Negative-QTOF | splash10-0002-1009000000-559b8fad12108c65816f | 2021-09-25 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Hyaluronic acid 20V, Negative-QTOF | splash10-0adi-3339000000-76adaf82a127143d0f78 | 2021-09-25 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Hyaluronic acid 40V, Negative-QTOF | splash10-052f-9523000000-abd6e76516deb9312be0 | 2021-09-25 | Wishart Lab | View Spectrum |
NMR SpectraSpectrum Type | Description | Deposition Date | Source | View |
---|
Predicted 1D NMR | 1H NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum |
|
---|
Biological Properties |
---|
Cellular Locations | |
---|
Biospecimen Locations | - Blood
- Cerebrospinal Fluid (CSF)
|
---|
Tissue Locations | Not Available |
---|
Pathways | |
---|
Normal Concentrations |
---|
| |
Blood | Detected and Quantified | 0.053 +/- 0.015 uM | Adult (>18 years old) | Both | Normal | | details | Blood | Detected and Quantified | <0.00496 uM | Adult (>18 years old) | Both | Normal | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | 0.0644 +/- 0.0528 uM | Not Specified | Not Specified | Normal | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | 0.214 +/- 0.0992 uM | Not Specified | Not Specified | Normal | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | 0.24 (0.12-0.36) uM | Adult (>18 years old) | Not Specified | Normal | | details |
|
---|
Abnormal Concentrations |
---|
| |
Blood | Detected and Quantified | 1.2 (0.04-10.52) uM | Adult (>18 years old) | Both | Biliary atresia | | details | Blood | Detected and Quantified | 0.11 (0.044-0.74) uM | Newborn (0-30 days old) | Both | Hepatitis | | details | Blood | Detected and Quantified | 0.11 +/- 0.013 uM | Adult (>18 years old) | Both | Diabetes | | details | Blood | Detected and Quantified | 0.00860 +/- 0.0103 uM | Adult (>18 years old) | Both | Uremia | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | >10.306 uM | Not Specified | Not Specified | Meningitis | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | >5.153 uM | Not Specified | Not Specified | Colon carcinoma | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | 0.0593-0.995 uM | Not Specified | Not Specified | Head injury | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | 0.25 (0.037-0.46) uM | Adult (>18 years old) | Not Specified | Epilepsy | | details |
|
---|
Associated Disorders and Diseases |
---|
Disease References | Biliary atresia |
---|
- Ukarapol N, Wongsawasdi L, Ong-Chai S, Riddhiputra P, Kongtawelert P: Hyaluronic acid: additional biochemical marker in the diagnosis of biliary atresia. Pediatr Int. 2007 Oct;49(5):608-11. [PubMed:17875085 ]
| Hepatitis |
---|
- Ukarapol N, Wongsawasdi L, Ong-Chai S, Riddhiputra P, Kongtawelert P: Hyaluronic acid: additional biochemical marker in the diagnosis of biliary atresia. Pediatr Int. 2007 Oct;49(5):608-11. [PubMed:17875085 ]
| Diabetes mellitus type 2 |
---|
- Mine S, Okada Y, Kawahara C, Tabata T, Tanaka Y: Serum hyaluronan concentration as a marker of angiopathy in patients with diabetes mellitus. Endocr J. 2006 Dec;53(6):761-6. Epub 2006 Sep 12. [PubMed:16966827 ]
| Uremia |
---|
- Vanholder R, De Smet R, Glorieux G, Argiles A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, Jorres A, Lemke HD, Massy ZA, Passlick-Deetjen J, Rodriguez M, Stegmayr B, Stenvinkel P, Tetta C, Wanner C, Zidek W: Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int. 2003 May;63(5):1934-43. doi: 10.1046/j.1523-1755.2003.00924.x. [PubMed:12675874 ]
| Epilepsy |
---|
- Perosa SR, Porcionatto MA, Cukiert A, Martins JR, Amado D, Nader HB, Cavalheiro EA, Leite JP, Naffah-Mazzacoratti MG: Extracellular matrix components are altered in the hippocampus, cortex, and cerebrospinal fluid of patients with mesial temporal lobe epilepsy. Epilepsia. 2002;43 Suppl 5:159-61. [PubMed:12121313 ]
| Meningitis |
---|
- Laurent UB, Laurent TC, Hellsing LK, Persson L, Hartman M, Lilja K: Hyaluronan in human cerebrospinal fluid. Acta Neurol Scand. 1996 Sep;94(3):194-206. [PubMed:8899053 ]
| Head injury |
---|
- Burke EJ, Mehlhorn U, Allen SJ: Hyaluronan in cerebrospinal fluid after head injury. Acta Neurol (Napoli). 1994 Jun;16(3):103-9. [PubMed:7992658 ]
|
|
---|
Associated OMIM IDs | |
---|
External Links |
---|
DrugBank ID | Not Available |
---|
Phenol Explorer Compound ID | Not Available |
---|
FooDB ID | FDB022824 |
---|
KNApSAcK ID | Not Available |
---|
Chemspider ID | 8020685 |
---|
KEGG Compound ID | C00518 |
---|
BioCyc ID | Not Available |
---|
BiGG ID | 35227 |
---|
Wikipedia Link | Hyaluronic acid |
---|
METLIN ID | Not Available |
---|
PubChem Compound | 53477741 |
---|
PDB ID | Not Available |
---|
ChEBI ID | 150712 |
---|
Food Biomarker Ontology | Not Available |
---|
VMH ID | HA |
---|
MarkerDB ID | MDB00000372 |
---|
Good Scents ID | rw1067861 |
---|
References |
---|
Synthesis Reference | Tan, Wensong; Hu, Yihong; Zhang, Xu; Cai, Haibo. Method for preparing hyaluronic acid from microbial fermentation broth. Faming Zhuanli Shenqing Gongkai Shuomingshu (2007), 10pp. |
---|
Material Safety Data Sheet (MSDS) | Not Available |
---|
General References | - Perosa SR, Porcionatto MA, Cukiert A, Martins JR, Amado D, Nader HB, Cavalheiro EA, Leite JP, Naffah-Mazzacoratti MG: Extracellular matrix components are altered in the hippocampus, cortex, and cerebrospinal fluid of patients with mesial temporal lobe epilepsy. Epilepsia. 2002;43 Suppl 5:159-61. [PubMed:12121313 ]
- Ghosh P, Guidolin D: Potential mechanism of action of intra-articular hyaluronan therapy in osteoarthritis: are the effects molecular weight dependent? Semin Arthritis Rheum. 2002 Aug;32(1):10-37. [PubMed:12219318 ]
|
---|